171 related articles for article (PubMed ID: 23573613)
1. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
Eidtmann H
Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
[No Abstract] [Full Text] [Related]
2. [DCIS and HER2/neu].
Tulusan AH
Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
[No Abstract] [Full Text] [Related]
3. [Combination therapy herceptin+taxotere/Herceptin+navelbine].
Meden H
Onkologie; 2002 Dec; 25 Suppl 5():15-6. PubMed ID: 23573614
[No Abstract] [Full Text] [Related]
4. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
6. Current perspective - trastuzumab.
Hall PS; Cameron DA
Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
9. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
Gujral DM; Lloyd G; Bhattacharyya S
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
[No Abstract] [Full Text] [Related]
11. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
[No Abstract] [Full Text] [Related]
12. Saving lives with accurate HER2 testing.
Ross JS
Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
[No Abstract] [Full Text] [Related]
13. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
14. T-DM1 Extends Survival in HER2+ Breast Cancer.
Cancer Discov; 2016 Feb; 6(2):OF4. PubMed ID: 26676162
[TBL] [Abstract][Full Text] [Related]
15. [Therapy concept: herceptin in combination with arimidex].
von Minckwitz G
Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
[No Abstract] [Full Text] [Related]
16. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
17. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
19. Information for patients. HER2: what you need to know.
Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
[No Abstract] [Full Text] [Related]
20. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
